INS and type 2 diabetes mellitus: Administration of GLP-1 to patients restores glucose-induced insulin secretion as well as the β-cells’ sensitivity to glucose and normalizes fasting and postprandial glycemia in T2D patients [3], but its application as an antidiabetic drug is made difficult by rapid degradation.